Back to Search Start Over

Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab

Authors :
Ho, Tiffany C.
Maamari, Robi N.
Kossler, Andrea L.
Sears, Connie M.
Freitag, Suzanne K.
Reshef, Edith R.
Shinder, Roman
Rootman, Daniel B.
Diniz, Stefania B.
Kahana, Alon
Schlachter, Dianne
Do, Thai H.
Kally, Peter
Turner, Sara
Mokhtarzadeh, Ali
Harrison, Andrew R.
Hwang, Christopher J.
Kim, Hee Joon
Avila, Sarah A.
Thomas, Dilip A.
Magazin, Maja
Wester, Sara T.
Lee, Wendy W.
Clauss, Kevin D.
Holds, John B.
Sniegowski, Matthew
Compton, Christopher J.
Briggs, Christian
Malik, Amina I.
Lucarelli, Mark J.
Burkat, Cat N.
Patel, Luv G.
Couch, Steven M.
Source :
Ophthalmic Plastic and Reconstructive Surgery; March-April 2023, Vol. 39 Issue: 2 p150-155, 6p
Publication Year :
2023

Abstract

Despite a national teprotumumab shortage resulting from COVID-19 pandemic, patients who were partially treated with teprotumumab achieve significant reduction in proptosis, clinical activity score, and extraocular muscle restriction and maintain these improvements during short-term interruption.

Details

Language :
English
ISSN :
07409303 and 15372677
Volume :
39
Issue :
2
Database :
Supplemental Index
Journal :
Ophthalmic Plastic and Reconstructive Surgery
Publication Type :
Periodical
Accession number :
ejs62432333
Full Text :
https://doi.org/10.1097/IOP.0000000000002267